Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. Chemotherapy. St. Luke's Hospital, Bethlehem, PA, United States

Survival: 9.7 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: United States
City/State/Province: Bethlehem, PA
Hospital: St. Luke's Hospital
Journal: Link
Date: 6/2009

This phase III trial involved advanced melanoma patients who had progressed following treatment with dacarbazine or temozolomide. Patients were divided into 2 separate treatment groups. Group A consisted of 135 patients with a median age of 56 years and 64% male. Group B had 135 patients with a median age of 57 years and 62% male.

Group A was treated with the chemotherapy agents carboplatin and paclitaxel. Group B was treated with carboplatin, paclitaxel, and the biologic therapy agent sorafenib.

The maximum toxicity level reported for group A was of grade 4 and included neutropenia (32% of patients with grade 4). Grade 3 sensory neuropathy was reported by 13% of patients.

There were 4 treatment-related deaths in group B. Causes included neutropenic sepsis (blood infection), and cerebral hemorrhage.

The median overall survival for both groups A and B was 9.7 months.

This study was supported by the pharmaceutical companies Bayer AG and Onyx Pharmaceuticals, Inc..

Correspondence: Sanjiv S. Agarwala; email:

E-mail to a Friend Email Physician More Information